TargetBeta
RAMP1
receptor activity modifying protein 1 · Receptor (G protein-coupled) activity modifying proteins
3 programs in company-led studies act on RAMP1, from 2 companies: 1 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| atogepantrule | AbbVie | phase 4 | 194 running | CALCRL | NCIt |
| ubrogepantrule | AbbVie | phase 4 | 133 running | CALCRL | NCIt |
| zavegepantrule | Pfizer | phase 3 | 131 running | CALCRL | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Migraine Disorders, 3 programs
- Asthma, 1 program
- COVID-19, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 2027ubrogepant · AbbVie · phase 4 · NCT05125302
- Aug 12, 2027zavegepant · Pfizer · phase 3 · NCT06995729
- Mar 2028atogepant · AbbVie · phase 4 · NCT05711394
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.